NCT02121990View on ClinicalTrials.gov

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 21, 2014

Primary Completion Date

August 19, 2020

Study Completion Date

August 19, 2020

Conditions
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
Interventions
DRUG

Paclitaxel,

DRUG

Bevacizumab

DRUG

Cisplatin

DRUG

Olaparib

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

07920

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER